Characteristics of patients with rheumatoid arthritis (RA).
| Characteristics | Patients with RA and No CV Risk Factor, n = 71 | Patients with RA and at Least 1 CV Risk Factor, n = 165 | p | Patients with RA, n = 236 |
|---|---|---|---|---|
| Demographics | ||||
| Age, yrs, median (range) | 52 (24–84) | 59 (29–87) | 0.002 | 57 (24–87) |
| Females, n (%) | 55 (77) | 137 (83) | 0.4 | 192 (81) |
| White, n (%) | 65 (92) | 135 (82) | 0.08 | 200 (85) |
| Disease characteristics | ||||
| Disease duration, yrs, median (range) | 14 (0–44) | 13 (0–45) | 0.5 | 13 (0–45) |
| Positive rheumatoid factor, n (%) | 51 (72) | 135 (82) | 0.1 | 186 (79) |
| Positive anti-CCP2 antibodies, n (%) | 56 (79) | 142 (86) | 0.2 | 198 (84) |
| Erosions on hand/foot radiographs, n (%) | 52 (73) | 134 (81) | 0.2 | 186 (79) |
| Disease activity: DAS28CRP, median (range) | 3.5 (1.2–7.1) | 3.6 (0.8–7.5) | 0.5 | 3.7 (0.8–7.5) |
| DAS28CRP > 3.2, n (%) | 34 (48) | 82 (50) | 0.9 | 116 (49) |
| DAS28CRP > 5.1, n (%) | 8 (11) | 25 (15) | 0.5 | 33 (14) |
| CRP (mg/l), median (range) | 6.5 (1–47) | 5 (1–57) | 0.9 | 5 (1–57) |
| CRP > 10 mg/l, n (%) | 24 (34) | 53 (32) | 0.9 | 77 (33) |
| HAQ, median (range) | 1 (0–3) | 1 (0–3) | 0.9 | 1 (0–3) |
| HAQ > 1.5, n (%) | 20 (28) | 39 (24) | 0.6 | 59 (25) |
| Treatment received | ||||
| Current corticosteroid use, n (%) | 60 (85) | 129 (78) | 0.3 | 189 (80) |
| Current conventional DMARD use, n (%) | 58 (82) | 142 (86) | 0.6 | 200 (85) |
| Current anti-TNF-α use, n (%) | 14 (20) | 40 (24) | 0.6 | 54 (23) |
| Current rituximab use, n (%) | 18 (25) | 60 (36) | 0.1 | 78 (33) |
| Current tocilizumab use, n (%) | 2 (3) | 5 (3) | 0.7 | 7 (3) |
| Current abatacept use, n (%) | 1 (1) | 6 (4) | 0.4 | 7 (3) |
| Cardiovascular risk factors | ||||
| Smokers, n (%) | 0 (0) | 107 (65) | < 0.0001 | 107 (46) |
| Hypertension, n (%) | 0 (0) | 77 (47) | < 0.0001 | 77 (32) |
| Diabetic, n (%) | 0 (0) | 28 (17) | 0.0005 | 28 (12) |
| Dyslipidemia, n (%) | 0 (0) | 37 (22) | < 0.0001 | 37 (16) |
| BMI > 30 kg/m2, n (%) | 0 (0) | 49 (30) | < 0.0001 | 49 (21) |
Anti-CCP2: anticyclic citrullinated peptide antibodies; DAS: Disease Activity Score; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; DMARD: disease-modifying antirheumatic drug; HAQ: Health Assessment Questionnaire; TNF: tumor necrosis factor; BMI: body mass index; CV: cardiovascular.